cysteinyl

N-[S-Trityl-L-cysteinyl]glycine is a cleavable ADC linker.

Cysteinylglycine acetate (Cys-Gly Acetate) is an acetate salt of Cysteinylglycine. Cysteinylglycine is an endogenous metabolite. Cysteinylglycine is used in disease diagnosis.

Cysteinyltyrosine is a dipeptide composed of cysteine and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism.

Cysteinylglycine (Cys-Gly), is a biologically important compound since it is formed during the γ-glutamyl cycle. It is a L-cysteinyl peptide, that can be used in the studies of many peptides and important proteins.

Cysteinylglycine TFA is an endogenous metabolite. It is used in disease diagnosis.

Cysteinylcysteine is a bioactive chemical.

Cysteinyllysine is a dipeptide composed of cysteine and lysine. It is an incomplete breakdown product of protein digestion or protein catabolism.

Homocysteinylpropachlor is a bioactive chemical.

5-S-Cysteinyldopamine is a thioether metabolite of dopamine that can induce neurological damage by causing extensive oxidative stress and protein aggregation. This is characterized by protein carbonylation, glutathione depletion, and increased expression of α-synuclein (α-Syn) and ERp57 proteins. It is applicable in research on neurodegenerative diseases such as Parkinson's disease.

Gemilukast (ONO-6950) is an orally active and potent dual inhibitor of cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2), inhibits LTC 4-induced bronchoconstriction, and is inhibitory to human CysLT1 and CysLT2, and may be used in the treatment of asthma.

Triciribine phosphate (VD 002) is a highly selective AKT inhibitor that induces cell cycle arrest and cysteinyl asparagin-dependent apoptosis, inhibits neovascularization, and can be used in the study of leukemia.

Pobilukast (SKF 104353) is a selective cysteinyl leukotriene receptor antagonist that blocks phosphatidylinositol metabolism and leukotriene D-induced thromboxane synthesis, and can be used to study limiting myocardial damage in excessively myocardial reperfusion-injured (MI R) rats.128-63-53-4

L-Glutathione reduced (Glutathione) is a naturally occurring tripeptide found in cells as an endogenous antioxidant that scavenges oxygen free radicals. L-Glutathione reduced is a cofactor for certain enzymes and is involved in the rearrangement of protein disulfide bonds and the reduction of peroxides.

Montelukast sodium (MK0476) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Pranlukast (ONO-1078) is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Montelukast (Singular) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP) and soluble epoxide hydrolase (sEH) inhibitor, exhibiting marked anti-inflammatory efficacy and high target selectivity.

HAMI 3379 is a potent and selective antagonist of the Cysteinyl leukotriene (CysLT2) receptor. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury. It also attenuates microglia-related inflammation.

LTD4 antagonist 2 (compound 6) functions as a leukotriene D4 (LTD4) antagonist with an IC50 of 2.8 μM for the cysteinyl leukotriene 1 receptor (CysLT1R). Additionally, it acts as an agonist for the G protein-coupled bile acid receptor 1 (GPBAR1), making it applicable for research into colitis, metabolic syndrome, and other GPBAR1- and CysLT1R-related diseases.

BAY-u 9773 is a non-selective antagonist of cysteinyl leukotrienes receptors (CysLT receptors), with approximately equal IC50 values for both CysLT1 and CysLT2. BAY-u 9773 is used to inhibit leukotriene responses [1].

LY 290324 is an orally active, potent and selective antagonist of cysteinyl leukotriene (LTD4) receptor.

Q8 is an antagonist of cysteinyl leukotreine receptor. Q8 inhibits VEGF-independent angiogenesis.

CP-85958 is a cysteinyl leukotriene antagonist.

Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1.